121 related articles for article (PubMed ID: 19104412)
21. Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody.
Shapiro R; Zeevi A; Basu A; Tan HP; Kayler LK; Blisard DM; Thai NL; Girnita AL; Randhawa PS; Gray EA; Marcos A; Starzl TE
Transplantation; 2008 Apr; 85(8):1125-32. PubMed ID: 18431232
[TBL] [Abstract][Full Text] [Related]
22. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation.
Shapiro R; Ellis D; Tan HP; Moritz ML; Basu A; Vats AN; Khan AS; Gray EA; Zeevi A; McFeaters C; James G; Jo Grosso M; Marcos A; Starzl TE
J Pediatr; 2006 Jun; 148(6):813-8. PubMed ID: 16769394
[TBL] [Abstract][Full Text] [Related]
23. Kidney transplantation achievements in Mongolia.
Jambaljav L; Nyamsuren D; Byambadash B; Ganbold L
Transplant Proc; 2010 Apr; 42(3):791-2. PubMed ID: 20430173
[TBL] [Abstract][Full Text] [Related]
24. Steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil: three-year results.
Borrows R; Loucaidou M; Van Tromp J; Singh S; Cairns T; Griffith M; Hakim N; McLean A; Palmer A; Papalois V; Taube D
Transplant Proc; 2005 May; 37(4):1792-4. PubMed ID: 15919468
[TBL] [Abstract][Full Text] [Related]
25. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation.
Pascual J; Pirsch JD; Odorico JS; Torrealba JR; Djamali A; Becker YT; Voss B; Leverson GE; Knechtle SJ; Sollinger HW; Samaniego-Picota MD
Transplantation; 2009 Jan; 87(1):125-32. PubMed ID: 19136902
[TBL] [Abstract][Full Text] [Related]
26. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD
Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276
[TBL] [Abstract][Full Text] [Related]
27. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
[TBL] [Abstract][Full Text] [Related]
28. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning.
Shapiro R; Jordan ML; Basu A; Scantlebury V; Potdar S; Tan HP; Gray EA; Randhawa PS; Murase N; Zeevi A; Demetris AJ; Woodward J; Marcos A; Fung JJ; Starzl TE
Ann Surg; 2003 Oct; 238(4):520-5; discussion 525-7. PubMed ID: 14530723
[TBL] [Abstract][Full Text] [Related]
29. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring.
Knechtle SJ; Pascual J; Bloom DD; Torrealba JR; Jankowska-Gan E; Burlingham WJ; Kwun J; Colvin RB; Seyfert-Margolis V; Bourcier K; Sollinger HW
Am J Transplant; 2009 May; 9(5):1087-98. PubMed ID: 19344431
[TBL] [Abstract][Full Text] [Related]
30. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
[TBL] [Abstract][Full Text] [Related]
31. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes.
Thai NL; Khan A; Tom K; Blisard D; Basu A; Tan HP; Marcos A; Fung JJ; Starzl TE; Shapiro R
Transplantation; 2006 Dec; 82(12):1621-4. PubMed ID: 17198247
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients.
Lim WH; Chang SH; Chadban SJ; Campbell SB; Dent H; Russ GR; McDonald SP
Transplantation; 2009 Nov; 88(10):1208-13. PubMed ID: 19935375
[TBL] [Abstract][Full Text] [Related]
33. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
34. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK
Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326
[TBL] [Abstract][Full Text] [Related]
35. Use of alemtuzumab (Campath-1H) as induction therapy in pediatric kidney transplantation.
Ona ET; Danguilan RA; Africa J; Cabanayan-Casasola CB; Antonio ZL; Gutierrez-Marbella MA; dela Cruz R; Bumanglag N; Espedilla ME
Transplant Proc; 2008 Sep; 40(7):2226-9. PubMed ID: 18790199
[TBL] [Abstract][Full Text] [Related]
36. Preemptive kidney transplant from deceased donors: an advantage in relation to reduced waiting list.
Pérez-Flores I; Sánchez-Fructuoso A; Calvo N; Marques M; Anaya S; Ridao N; Rodríguez A; Barrientos A
Transplant Proc; 2007 Sep; 39(7):2123-4. PubMed ID: 17889112
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of 115 pediatric renal transplant recipients with tacrolimus-based immunosuppressive therapy: a 7-year multicenter study in Japan.
Hasegawa A; Oshima S; Takahashi K; Uchida K; Ito K; Sonoda T
Transplant Proc; 2005 May; 37(4):1769-70. PubMed ID: 15919460
[TBL] [Abstract][Full Text] [Related]
38. Preemptive living donor renal transplantation: a single-center experience.
Haberal M; Karakayali H; Sevmis S; Akbulut S; Colak T; Baskin E; Moray G; Torgay A; Arslan G
Transplant Proc; 2009 Sep; 41(7):2764-7. PubMed ID: 19765429
[TBL] [Abstract][Full Text] [Related]
39. Deceased donor organ transplantation with expanded criteria donors: a single-center experience from India.
Goplani KR; Firoz A; Ramakrishana P; Shah PR; Gumber MR; Patel HV; Vanikar AV; Trivedi HL
Transplant Proc; 2010; 42(1):171-4. PubMed ID: 20172307
[TBL] [Abstract][Full Text] [Related]
40. Evolutionary experience with immunosuppression in pediatric intestinal transplantation.
Bond GJ; Mazariegos GV; Sindhi R; Abu-Elmagd KM; Reyes J
J Pediatr Surg; 2005 Jan; 40(1):274-9; discussion 279-80. PubMed ID: 15868597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
